Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial

Del-desiran failed the Phase III HARBOR trial (NCT06411288) by missing the study’s primary endpoint of statistically significant improvement vs. placebo in video Hand Opening Time (vHOT) through week 54. vHOT is a frequently used measure of hand myotonia, according to a 2024 study, and involves clinical experts reviewing videos to measure the time from hand grip to opening.

The post Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial appeared first on GEN - Genetic Engineering and Biotechnology News.